Gastric Cancer

Gastric cancer is a useful berberine setting because inflammatory signalling and glucose-handling biology both appear central to the response.

Why berberine is relevant here

The strongest recurring themes in gastric models are:

• JAK2 / STAT3 suppression

• reduced inflammatory drive

• GLUT1-linked glycolysis inhibition

• stronger growth suppression under low-glucose conditions

That makes gastric cancer one of the clearest tumour types for combining berberine with broader metabolic strategies.

Main mechanisms in gastric cancer

JAK2 / STAT3 inhibition

Berberine suppresses JAK2 / STAT3 signalling and reduces IL-6-linked inflammatory drive.

This matters because STAT3 is a common survival and immune-evasion pathway in gastric cancer.

Low-glucose synergy

Some gastric-cancer work suggests berberine becomes more effective under low-glucose conditions.

That supports the broader idea that berberine can intensify metabolic stress where tumour cells are already pressured.

GLUT1 and Warburg-effect reversal

Gastric models also feature prominently in the GLUT1 / Akt / mTOR work.

Reported findings include reduced glucose uptake, lower ATP availability, and impaired glycolytic survival.

Practical interpretation

Gastric cancer is one of the better berberine pages for readers interested in the overlap between tumour metabolism and inflammation.

The key practical point is not that berberine is proven therapy.

It is that gastric cancer offers one of the clearest mechanistic rationales for combining berberine with glucose-restriction or other metabolic strategies under proper supervision.

References

Gastric Cancer ⭐⭐⭐⭐

JAK2/STAT3 pathway — primary mechanistic study (in vivo confirmed):

Xu J, et al. (2022). Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6. Life Sciences, 290:120266.
🔗 https://pubmed.ncbi.nlm.nih.gov/34968467/[pubmed.ncbi.nlm.nih](https://pubmed.ncbi.nlm.nih.gov/34968467/)

Molecular landscape review (2026 — gastric + GI breadth):

(2026). Molecular landscape of Berberine's therapeutic potential in gastric and gastrointestinal cancers. PMC.
🔗 https://pmc.ncbi.nlm.nih.gov/articles/PMC12884497/[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC12884497/)[https://pmc.ncbi.nlm.nih.gov/articles/PMC12365213/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12365213/)